Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Watkins

Showing results (301-310 of 320) with videos related to

Pageof 32
Sort By:
Blood|November 15, 2021
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphomaJeffrey P Ward, Melissa M Berrien-Elliott, Felicia Gomez, et al.
Leukemia & Lymphoma|November 2, 2022
A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphomaMatthew J Cortese, Wei Wei, Sebastian Cerdeña, et al.
Blood|February 9, 2026
Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy ResistanceHannah K Dorando, Jared M Andrews, Oam U Khatavkar, et al.
Nature Cell Biology|September 16, 2025
Two microbiome metabolites compete for tRNA modification to impact mammalian cell proliferation and translation quality controlWen Zhang, Kuldeep Lahry, Denis Cipurko, et al.
Nature Communications|December 9, 2021
Author Correction: Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behaviorJ Blaze, A Navickas, H L Phillips, et al.
Nature Communications|August 14, 2021
Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behaviorJ Blaze, A Navickas, H L Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance MechanismsHanna Tukachinsky, Russell W Madison, Jon H Chung, et al.
Blood Advances|July 26, 2023
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303David A Russler-Germain, Kilannin Krysiak, Cody Ramirez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Pageof 32

Showing results (301-310 of 320) with videos related to

Sort By:
Pageof 32
Blood|November 15, 2021
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphomaJeffrey P Ward, Melissa M Berrien-Elliott, Felicia Gomez, et al.
Leukemia & Lymphoma|November 2, 2022
A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphomaMatthew J Cortese, Wei Wei, Sebastian Cerdeña, et al.
Blood|February 9, 2026
Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy ResistanceHannah K Dorando, Jared M Andrews, Oam U Khatavkar, et al.
Nature Cell Biology|September 16, 2025
Two microbiome metabolites compete for tRNA modification to impact mammalian cell proliferation and translation quality controlWen Zhang, Kuldeep Lahry, Denis Cipurko, et al.
Nature Communications|December 9, 2021
Author Correction: Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behaviorJ Blaze, A Navickas, H L Phillips, et al.
Nature Communications|August 14, 2021
Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behaviorJ Blaze, A Navickas, H L Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance MechanismsHanna Tukachinsky, Russell W Madison, Jon H Chung, et al.
Blood Advances|July 26, 2023
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303David A Russler-Germain, Kilannin Krysiak, Cody Ramirez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Pageof 32